Free Trial

Forte Biosciences Sees Unusually Large Options Volume (NASDAQ:FBRX)

Forte Biosciences logo with Medical background

Forte Biosciences, Inc. (NASDAQ:FBRX - Get Free Report) was the recipient of some unusual options trading activity on Wednesday. Traders purchased 30,205 call options on the stock. This is an increase of 1,663% compared to the typical daily volume of 1,713 call options.

Forte Biosciences Stock Performance

Shares of NASDAQ:FBRX traded down $1.03 on Thursday, hitting $11.45. The stock had a trading volume of 113,360 shares, compared to its average volume of 172,551. The firm's 50 day moving average price is $10.19 and its 200-day moving average price is $10.96. Forte Biosciences has a twelve month low of $4.11 and a twelve month high of $28.68. The company has a market capitalization of $75.38 million, a price-to-earnings ratio of -0.70 and a beta of 2.97.

Forte Biosciences (NASDAQ:FBRX - Get Free Report) last announced its earnings results on Thursday, May 15th. The company reported ($1.37) EPS for the quarter, missing the consensus estimate of ($0.89) by ($0.48). As a group, sell-side analysts predict that Forte Biosciences will post -12.12 EPS for the current year.

Analyst Upgrades and Downgrades

FBRX has been the topic of a number of research reports. Chardan Capital reissued a "buy" rating and set a $61.00 target price on shares of Forte Biosciences in a report on Tuesday, June 24th. Wall Street Zen lowered shares of Forte Biosciences from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd.

View Our Latest Report on FBRX

Institutional Trading of Forte Biosciences

A number of hedge funds have recently made changes to their positions in the company. Garde Capital Inc. bought a new stake in Forte Biosciences during the 1st quarter valued at $31,000. AlphaQuest LLC bought a new position in shares of Forte Biosciences during the 1st quarter valued at approximately $33,000. JPMorgan Chase & Co. raised its holdings in shares of Forte Biosciences by 70,000.0% in the 4th quarter. JPMorgan Chase & Co. now owns 2,103 shares of the company's stock worth $48,000 after purchasing an additional 2,100 shares during the period. Geode Capital Management LLC raised its stake in shares of Forte Biosciences by 18.3% in the fourth quarter. Geode Capital Management LLC now owns 16,877 shares of the company's stock valued at $383,000 after buying an additional 2,607 shares during the period. Finally, Acuta Capital Partners LLC bought a new stake in shares of Forte Biosciences in the fourth quarter valued at $412,000. 77.63% of the stock is owned by institutional investors and hedge funds.

Forte Biosciences Company Profile

(Get Free Report)

Forte Biosciences, Inc operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc is headquartered in Dallas, Texas.

Recommended Stories

Should You Invest $1,000 in Forte Biosciences Right Now?

Before you consider Forte Biosciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Forte Biosciences wasn't on the list.

While Forte Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines